Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.07 USD +3.47% Intraday chart for Black Diamond Therapeutics, Inc. -6.28% +80.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board CI
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535 CI
Black Diamond Therapeutics, Inc. Announces Management Changes CI
Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes CI
Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer CI
Certain Restricted Stock Units of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Certain Warrants of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Certain Stock Options of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Certain Common Stock of Black Diamond Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-AUG-2023. CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Black Diamond Therapeutics Discloses Institutional Shareholder Equity Stake Expansion; Shares Jump Premarket MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
Black Diamond Therapeutics Prices $75 Million Common Stock Offering MT
Top Premarket Decliners MT
Black Diamond Therapeutics Launches $75 Million Stock Offering; Shares Drop After-Hours MT
Insider Sell: Black Diamond Therapeutics MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
Sector Update: Health Care Stocks Softer Late Tuesday MT
Sector Update: Health Care Stocks Easing Tuesday Afternoon MT
Chart Black Diamond Therapeutics, Inc.
More charts
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.07 USD
Average target price
10.6 USD
Spread / Average Target
+109.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Black Diamond Therapeutics, Inc. - Nasdaq
  4. News Black Diamond Therapeutics, Inc.
  5. Black Diamond Therapeutics : Earnings Flash (BDTX) BLACK DIAMOND THERAPEUTICS Posts Q2 Loss $-0.95